Here we investigated the influence of parameters known before hematopoietic stem cell transplantation (HSCT) as well as the relevance of graft-versus-host disease (GvHD) and cytomegalovirus (CMV) reactivation on post transplant lymphocyte reconstitution in 148 patients treated in our institution between 1996 and 2003. Median patient age was 42 (19-68) years, HSCT followed standard high dose (n ¼ 91) or reduced-intensity conditioning regimens (n ¼ 57) with bone marrow (BM, n ¼ 67) or peripheral blood stem cells (PBSC, n ¼ 81) from related (n ¼ 71) or unrelated (n ¼ 77) donors. In the first months, we observed a partially faster reconstitution of CD3
and CD4 þ 45RA þ T cells in patients following peripheral blood stem cell transplantation when compared to bone marrow transplantation. Prolonged CD3 þ 4 þ and CD4 þ 45RA þ lymphopenia was noted after unrelated donor HSCT and GvHD prophylaxis containing anti-T-lymphocyte globulin. Lymphocyte subset counts in patients older than the median age were comparable to those in patients transplanted at a younger age and not influenced by the conditioning regimen. CD3 þ 8 þ T cell reconstitution was strongly correlated with CMV reactivation, but not significantly affected by CMV serostatus before HSCT. Incidence or extent of GvHD did not significantly influence lymphocyte reconstitution. Therefore, the source of graft is the most predictive parameter in early lymphocyte reconstitution, but the differences in lymphocyte recovery completely resolved within the first year after HSCT.
Introduction
The incidence of post-engraftment infections is mainly due to a delayed reconstitution of lymphocytes, especially the B cells 1 and CD4 þ T cells. 2 Besides an increased susceptibility for opportunistic infections, imbalances in immune reconstitution can result in insufficient control of residual disease, whereas impaired T cell tolerance contributes to the development of graft-versus-host disease (GvHD). Recently, published studies suggest that rapid T cell reconstitution may correlate positively with overall survival after allogeneic hematopoietic stem cell transplantation (alloHSCT). 3, 4 For these reasons, restoration of the immune system following alloHSCT remains a focus of ongoing research.
Possibly due to their early recovery after HSCT, reconstitution of cells contributing to innate immunity has not been studied that extensively so far. In this context, recently published studies emphasized the role of natural killer (NK) cells in a mismatch transplant setting 5 and several investigations have now pointed out the influence of dendritic cells on both, innate and adaptive immune responses to infections or residual disease. 6 Particularly, during the early period after alloHSCT, these cells seem to have a remarkable impact on avoidance of infectious diseases in place of the later reconstituting adaptive immune system. 7 Concerning investigation of T cell subsets, several functional assays such as quantification of T cell receptor excision circles (TRECs) or assessment of T cell receptor (TCR) repertoire diversity by CD3R spectratyping have contributed to elucidate immune reconstitution after alloHSCT in the last years. 8, 9 However, owing to their complexity and costs these techniques are hardly applicable in a clinical setting and for that reason more restricted to defined scientific questions. Therefore, determination of lymphocyte subsets by flow cytometry remains a valid and routinely practicable method to characterize the risk for infections in patients after allogeneic transplantation. Several studies have analyzed the role of defined parameters in lymphocyte reconstitution after alloHSCT [10] [11] [12] [13] [14] [15] and immune reconstitution has been found to be influenced by the source of graft (peripheral blood stem cells (PBSC) vs bone marrow (BM)), [10] [11] [12] [13] type of conditioning, 16 incidence or extent of GvHD, 17 cytomegalovirus (CMV) reactivation or the CMV serostatus before HSCT. 18 However, most of these studies are hampered, because the role of defined parameters was investigated in relatively small cohorts of patients, mostly with focus on the source and cellular composition of the graft. In our study, we retrospectively investigated all parameters potentially affecting immune reconstitution in a comparatively large group of patients. As introduction of reduced-intensity conditioning (RIC) regimens [19] [20] [21] has extended the use of HSCT to a group of elderly patients with a consecutively increasing number of alloHSCTs in this population, we also focused on the influence of patient age and the conditioning regimen. Immune reconstitution in this setting has not been studied extensively so far.
Patients and methods

Patients and transplantation parameters
We routinely perform lymphocyte regeneration studies at 1, 3, 6 and 12 months after alloHSCT. Between January 1996 and July 2003, a total of 936 lymphocyte subset determinations from 356 patients who underwent alloHSCT in our institution were performed. In order to avoid influence of unknown parameters like patient availability and to analyze the evolution of lymphocyte subsets in each patient more precisely, we finally focused on 148 patients from whom lymphocyte recovery data existed from 1, 3-6 and 9-12 months. Patient characteristics are shown in Table 1 .
GvHD prophylaxis and supportive care were performed according to standard methods in alloHSCT as formerly described. 22 In cases of unrelated donor HSCT or transplantation from a partially mismatched related donor, patients received rabbit anti-T-lymphocyte globulin (ATG-S, Fresenius, Graefelfing, Germany) intravenously on days À3 to À1. CMV monitoring was performed weekly by polymerase chain reaction (PCR) for the detection of CMV in the peripheral blood. In case of two consecutive positive PCR results, treatment with ganciclovir (5 mg/kg every 12 h for 5 days, thereafter every 24 h) or foscarnet (60 mg/kg every 12 h for 14 days, thereafter every 24 h) was started and continued until a negative PCR result was obtained.
Determination of lymphocyte subsets
Peripheral blood cells were quantified and automatically differentiated on an electric counter (STKS Coulter, Krefeld, Germany). Determination of lymphocyte subsets was performed on days þ 30, þ (90 to) 180 and þ (270 to) 365 after HSCT with a whole blood lysing procedure according to the manufacturer's recommendations (Becton Dickinson, Heidelberg, Germany). Following combinations were used: CD3-FITC/CD4-PE (helper/inducer-T lymphocytes), CD3-FITC/CD8-PE (cytotoxic/suppressor-T lymphocytes), CD19-PE (B lymphocytes), CD3-FITC/ CD16/56-PE (NK cells), CD14-FITC/CD45-PE (monocytes), CD4-FITC/CD45R0-PE ('memory' helper/inducer-T cells) and CD45RA-FITC/CD4-PE ('naive' helper/ inducer-T cells). After addition of 2 ml lysing solution for 15 min, cells were washed and measured on a FACScan or FACS caliber. Gating and estimation of gated lymphocytes were performed according to the guidelines of the National Institute of Allergy and Immunologic Diseases (NIAID). 23 
Statistical analysis
The observation period was restricted to the first year after HSCT with lymphocyte subset determinations after 1, (3 to) 6 and (9 to) 12 months. All measurements of lymphocyte counts were logarithmically transformed in order to obtain data showing symmetric distributions, and the following statistical analyses were based on logtransformed values. The use of ATG before HSCT was Statistical analysis was performed by a uni-and a multivariate statistical model (repeated measures analysis of variance) using the program SAS 6.12. (SAS/STAT software). We compared the stated parameters in each group of patients at each time interval as well as the evolution of defined parameters in these groups over the time of the observation period. All tests were two-sided with a significance level Po0.05. In case of significant differences in the univariate statistical analysis, multivariate analysis was performed. Finally, the following variables were analyzed in a multivariate model: donor, graft, conditioning regimen, age of the recipient and the donor, CMV serostatus and CMV reactivation. Results in Figures  1-3 illustrate median and range of determined lymphocyte subsets, horizontal lines show 5th and 95th percentile of normal distribution, and stars mark significant differences. Tables 2-4 .
Statistical analysis with corresponding P-values is shown in
Results
Evolution of lymphocyte subsets and NK cells during the first year after HSCT Total lymphocyte counts (TLC) increased continuously during the observation period but failed to reach normal ranges during the first 6 months. CD19 þ B cells were clearly reduced the first months and normalized after 1 year in most patients. In contrast, normal to increased circulating NK cells occurred already by 1 month. Counts of CD3 þ T cells returned to normal after 6 months mainly because of a rapid regeneration of CD8 þ T cells. CD4 þ T cells regenerated later and most patients failed to reach normal counts within the first year. At this point in time, CD4 þ T cell counts had normalized in only 21% of patients, in 43% their number did not surpass 200 Â 10 6 /l. Correspondingly, we found an inverse CD3
subtype, as the number of naive T cells did not increase essentially during the first months, whereas counts of the CD4 þ 45R0 þ subtype showed an adequate reconstitution resulting in approximately normal counts after 1 year.
Results of univariate statistical analysis
Results of univariate statistical analysis and significant P-values are shown in Table 2 . Peripheral blood stem cell transplantation (PBSCT) was associated with significantly higher T cell subset counts during the first months after alloHSCT when compared to BMT: after 1 month, we noted a faster reconstitution of total lymphocytes, (Figure 1a and b) and CD4 þ 45R0 þ T cells (Figure 1c ). These temporary differences in 
CD4
þ 45RO þ T cells (Figure 2c) was not influenced by the donor type. CD4
þ 45RA þ T cell counts ( Figure 2d ) were consistently higher in the related group during the first 6 months. Again, after 1 year we found no significant difference in lymphocyte subset recovery among both groups. CMV reactivation during the first year was Lymphocyte reconstitution after allogeneic hematopoietic SCT C Heining et al associated with higher CD3 þ 8 þ T cell counts ( Figure 3 ) and a decreased CD3
ratio when compared to patients with absent CMV reactivation. In contrast, CMV serostatus of donor and recipient before HSCT did not significantly influence reconstitution of CD3 þ 8 þ T cells. Further, lymphocyte reconstitution was not significantly correlated with the occurrence of GvHD or the conditioning regimen when RIC and standard highdose regimens were compared.
Results of multivariate statistical analysis
Univariate analysis demonstrated a partially faster lymphocyte reconstitution in patients following PBSCT or related donor transplantation. We also found T cell reconstitution correlated with CMV reactivation. As one aim of the study was to evaluate lymphocyte reconstitution in dependence of the patient age and the type of conditioning regimen more precisely, these additional parameters were included in our multivariate statistical analysis. Therefore, following variables were investigated in this analysis: donor, graft, conditioning regimen, age of recipient and the donor, CMV serostatus and CMV reactivation.
We found reconstitution of lymphocyte subsets primarily to be correlated with the type of donor, the source of graft and appearance of CMV reactivation after HSCT. Results are shown in Table 3 . Regarding lymphocyte reconstitution over time, a consistent increase of all examined lymphocyte subsets during the first year after HSCT was confirmed.
PBSCT resulted in higher counts of total lymphocytes (Po0.01), CD3 Correlation of lymphocyte reconstitution, CMV serostatus and CMV reactivation Twenty-nine out of 75 patients with negative CMV serostatus before HSCT underwent transplantation from CMV seropositive donors, and 73 patients with positive pretransplant CMV serostatus were transplanted from 33 seropositive and 40 seronegative donors. Although CMV viremia during the first year after HSCT was observed more rarely in patients with negative pretransplant CMV serostatus, 52 patients with positive CMV serostatus before HSCT developed CMV reactivation during the observation period. In none of our investigated patients we found documented CMV disease within the first year after HSCT.
CMV reactivation during the observation period resulted in higher counts of CD3 þ 8 þ T cells (Po0.001, Figure 3 ) and a consecutively decreased CD4 þ to CD8 þ ratio (Po0.001). In case of CMV reactivation, the number of CD3 þ 8 þ T cells recovered to and above normal levels within 6 (866 Â 10 6 cells/l) and 12 months (1203 Â 10 6 cells/l), whereas counts in patients with absent CMV reactivation remained within the lower normal range (221 and 300 Â 10 6 cells/l after 6 and 12 months, respectively). Corresponding to a higher risk for CMV viremia in the group of CMV seropositive patients, a positive CMV serostatus before HSCT was associated with higher levels of the CD3 þ 8 þ subtype after 6 and 12 months, but these differences did not reach a statistically significant level. The remaining lymphocyte subsets were not essentially influenced by CMV serostatus or reactivation.
Lymphocyte reconstitution in dependence of patient age and conditioning regimen In order to get more detailed information on the influence of patient age, lymphocyte recovery in patients older than the median age of 42 years (43-68 years) was compared with reconstitution in patients transplanted at younger age (19-42 years) . Effects of the conditioning regimen were investigated by comparing standard high-dose to RIC regimens as stated above. Both parameters finally were included in our multivariate statistical analysis.
Results in dependence of the patient age are summarized in Table 4 . Among both groups, there was a comparable ratio of related and unrelated HSCT (48% related and 52% unrelated donors in the group p42 years vs 49 and 51% in the group 442 years) and we found no significant difference with respect to the donor age. Elderly patients more frequently received a RIC regimen (n ¼ 46) when compared to the younger group (n ¼ 11) and preferably were grafted with PBSC (n ¼ 50 vs n ¼ 32 in the younger group, respectively). Diagnosis of ALL (n ¼ 2) and chronic myelogenous leukemia (n ¼ 16) was comparatively rare in the elderly group, whereas more patients suffered from multiple myeloma (n ¼ 6) and NHL (n ¼ 12). In most cases, disease status in the elderly patients was considered to be unfavorable (n ¼ 50).
In part, we found a trend toward a more rapid lymphocyte reconstitution in the elderly group. In univariate analysis, there was a superior reconstitution of CD3 þ T cells (1012 vs 641 Â 10 6 cells/l, P ¼ 0.004) and CD4 þ 45R0 þ memory T cells (251 vs 163 Â 10 6 cells/l, P ¼ 0.04) 1 year after HSCT. Most other lymphocyte subset counts tended to be higher in the elderly group, but these differences did not obtain statistical significance (Table 4) . In no case, we found higher patient age to be correlated with delayed lymphocyte reconstitution. Same observations were made when the influence of patient age was investigated in subgroups of patients. Table 4 includes those subgroups of patients in which we primarily suspected a negative influence of age such as patients after unrelated donor transplantation and patients following BMT or standard high-dose regimens. In none of these distinctive patient groups, was an age-related decrease in lymphocyte recovery found. The same was true for their corresponding counterparts (e.g. patients following RIC, data not shown). Multivariate analysis confirmed a comparable lymphocyte subset reconstitution with regard to the patient age. Slightly higher TLC were noted in patients transplanted at an age greater than 42 years (1490 vs 1080 Â 10 6 cells/l, Po0.05). Regarding the age of the donor, for the majority of lymphocyte subsets we found no significant differences in immune reconstitution except for a faster reconstitution of CD3 þ 4 þ cells and a higher CD4 þ to CD8 þ ratio after HSCT from a donor older than 38 years. As mentioned above, conditioning protocols did not influence T cell reconstitution, when standard high-dose and RIC regimens were compared. Only the use of TBI as a part of the regimen correlated with delayed reconstitution of CD19 þ B lymphocytes (Po0.05).
Discussion
The important results of our study are as follows: first, a significantly faster reconstitution of CD3 þ 4 þ and CD4
þ 45RA þ T lymphocytes in patients grafted with PBSC or transplanted from a related donor without the use of ATG. Second, lymphocyte reconstitution was not significantly affected by patient age and the conditioning regimen, whereas recovery of CD3 þ 8 þ T cells was clearly associated with CMV reactivation. Of note, most differences in early immune reconstitution resolved during the observation period with the result of comparable lymphocyte subset counts among the investigated groups 1 year after alloHSCT. CD4
þ T cell counts 4200 Â 10 6 /l were reached in less than the half of patients at this point of time.
Some of these results confirm the data of previous investigations. As mentioned above, the majority of these studies investigated immune reconstitution in small cohorts of patients. Although a comparatively large cohort in our study caused a more heterogeneous patient group, multivariate analysis of our data allowed for a valid investigation of a variety of possibly influencing parameters such as disease type and status, transplant protocol or the age of donor and recipient. Regardless of these parameters, the study points out the impact of the source of graft as well as the relevance of differences in a related or unrelated transplant setting, such as T cell depleting therapy with the use of ATG.
In our study, we included patients from whom lymphocyte recovery data existed at each point of time within the first 12 months after HSCT. This decision primarily was made to avoid an influence of unknown parameters like patient availability or compliance and allowed for a more precise analysis and statistical evaluation of lymphocyte subset evolution in each patient. On the other hand, it implied exclusion of patients who did not survive this period of time, which must be considered in interpretation of our data. However, as mortality following HSCT is often caused by numerous coexisting or rapidly succeeding complications it would be difficult to separate the influence of definite parameters like recurrence of malignancy, infection, GvHD or treatment of these events on immune reconstitution in this setting.
We found prolonged lymphopenia of CD4 þ , CD4
þ 45RA þ and in part CD8 þ T cells after BMT when compared to PBSCT. These observations may be attributed to the cellular composition of granulocyte colony-stimulating factor mobilized grafts, as they contain more than 10-fold higher counts of CD4 þ and CD8 þ T cells, that may survive in the recipient for a long time post transplant. [24] [25] [26] Therefore, it can be supposed that recovery of these subsets after HSCT is correlated with the number of T cells transfused with the graft. In line with this assumption, depressed immune reconstitution was demonstrated follow-ing HSCT from T cell-depleted grafts. 27 Rather than an effect of relatedness itself, similar considerations may also explain the delayed reconstitution of CD4 þ T cells we observed in patients who underwent in vivo T cell depletion by the use of ATG before unrelated or partially mismatched donor HSCT. However, advantages in early T cell recovery appeared to be lost subsequently during the observation period and after 1 year comparable CD4 þ T cell counts were noted regardless of the source of graft or donor type. Recently published studies 3 have found a positive correlation between rapid CD4 þ lymphocyte recovery and outcome after transplantation. Our data suggest that, independent of investigated risk factors for delayed immune reconstitution during the first months, there is a comparable lymphocyte reconstitution 1 year after HSCT. Of note, our study included patients who were available for evaluation and therefore alive at this point in time. Therefore, it seems that the influence of identified risk factors for delayed lymphocyte reconstitution and may be patient outcome primarily takes place in the first months, whereas there is a comparable immune reconstitution in patients who survived this vulnerable period after HSCT.
One aim was to investigate immune reconstitution in dependence of the patient age and the conditioning regimen. Among other things, introduction of RIC regimens has extended the use of HSCT to a group of elderly patients. 19, [28] [29] [30] The impact of non-myeloablative regimens on immune reconstitution is discussed controversially, as there are limited investigations, often based on relatively small cohorts of patients. A prolonged CD4 þ 45RA þ and CD4 þ 45RO þ lymphopenia was reported after RIC containing cladribine, busulfan and ATG. 31 On the other hand, higher post transplant CD4 þ 45RA þ levels were observed in the early period after RIC when compared to myeloablative HSCT. 32 Other authors found a superior immunity in non-myeloablative HSCT recipients early after transplantation, whereas counts of total and naive CD4 þ T cells were higher in myeloablative patients after 1 year. 33 These different observations in immune reconstitution after RIC are probably due to the variability of the used protocols as well as the variable use of ATG or immunosuppressants in several investigations concerning this issue. Anyway, in a comparatively large cohort of patients we found comparable lymphocyte subsets following RIC or standard highdose transplantation at each point of time and therefore no statistically reliable evidence for a benefit of one type of conditioning protocol. Regarding the patient age, lymphocyte reconstitution in elderly patients was competitive and we found a trend toward a faster lymphocyte reconstitution in these patients. As we observed a delayed immune reconstitution following BMT, the higher number of PBSC grafts in the elderly group might have been a reasonable explanation. This was supported by the observation of a superior CD4 þ T cell reconstitution during the first 6 months in elderly patients who underwent transplantation from an elderly donor. These patients may represent a group preferably transplanted with PBSC from an elderly related donor without the use of ATG. On the other hand, analysis of distinctive subgroups such as patients following HSCT after ablative regimens or patients grafted with BM did not indicate an age-related delay in lymphocyte reconstitution as well. Therefore, at least quantitative lymphocyte reconstitution seems to be independent of the patient age. Moreover, an interesting result in this context may be the observation that regeneration of CD4 þ 45RA þ T cells was independent of the patient age. As mentioned above, functional assays such as quantification of TRECs or assessment of TCR repertoire diversity have contributed to give insight into the nature of immune reconstitution and to investigate thymic function in the transplant setting. 8, 9 In corresponding investigations, a limited diversity in TCR repertoire and low TREC levels, as an indicator for reduced thymic output, 34 were observed during the early post transplant period. Therefore, early recovery of CD4 þ T cells seems to be attributed to peripheral expansion of CD4 þ 45RO þ memory T cells derived from cells transfused with the graft, whereas expansion of CD4 þ 45RA þ cells is strongly decreased at this point of time. 8 As reconstitution of this naive phenotype in contrast to extrathymically expanded memory T cells depends on the thymusdependent pathway, 35 a prolonged reconstitution in the elderly group would not have been surprising. However, we found the expected higher level of the CD4 þ 45R0 þ subtype without relevant differences among the groups and a prolonged reconstitution of the CD4 þ 45RA þ phenotype that was influenced by the source of graft and the donor type but not associated with the patient age.
Subclinical CMV reactivation resulted in significantly improved CD3 þ 8 þ T cell recovery. In case of CMV reactivation, their number increased continuously and exceeded the normal range 1 year after HSCT, whereas reconstitution of this subset was comparatively moderate in patients with absent CMV reactivation. As cytotoxic CD8 þ T cells play an important role in immunological protection from CMV disease, the observation may primarily be attributed to an upregulation in case of CMV antigen exposure. Former investigations in bone marrow recipients indicate that the presence of CMV antigen can induce an expansion of CD3 þ 8 þ T cells with clonal predominance of CMV-specific CD8 þ cytotoxic T cells. 36 These data are in line with observations in B-cell chronic lymphocytic leukemia patients, where an expansion of CD8 þ T cells was related to CMV infection. 37 There also seems to be a potent stimulation of T cell function by subclinical CMV infections. 18 Furthermore, T cell recovery was suggested to be influenced by the anti-viral treatment itself, 38 when ganciclovir prophylaxis and pre-emptive therapy were compared, but these treatment-related observations were not made consistently. 18 Therefore, the elevated number of CD3 þ 8 þ T cells in patients who developed CMV antigenemia may reflect a persistent expansion of clonal CMV-specific CD8 þ T cells rather than a generalized acceleration of CD8 þ T cell reconstitution in these patients.
Quantitative immune reconstitution was not affected by the occurrence or the extent of GvHD during the first year after HSCT. Concerning post transplant T cell recovery and its influence on GvHD, effects and expansion of regulatory (CD4 þ 25 þ ) T cells are one focus of ongoing research. Primarily because of their effects in controlling autoimmunity and therefore GvHD after HSCT, application of ex vivo expanded regulatory T cells seems to be a promising therapeutic approach to achieve a modulation of effector T cells and thus prevention from GvHD. 39, 40 On the other hand, chronic GvHD and its treatment were reported to influence immune reconstitution. In this context, an impaired reconstitution of B cells was noted in case of extensive chronic GvHD. [41] [42] [43] Although previous investigations suggested poor T cell reconstitution due to thymic injury by GvHD, 44 recently published data showed no differences in T cell subset counts and TREC levels in dependence of GvHD. 45 This is in line with our observations, where we found no significant differences in T cell reconstitution with respect to incidence and extent of GvHD. B lymphocyte recovery returned to normal 1 year after HSCT and was delayed in case of steroids as a part of GvHD prophylaxis, but not influenced by the occurrence of GvHD or following immunosuppression with the use of steroids after HSCT. First observation approximately corresponds with former investigations. In these studies, 24 ,46-47 normalization of B lymphocytes after BMT was reported from 6 to 11 months post transplant using CsA and MTX for GvHD prophylaxis and a pronounced B lymphopenia during the first 6 months occurred in patients who had received steroids as a part of their GvHD prophylaxis. 22 Taken together, neither CMV serostatus nor sex, diagnosis, disease status, nor the conditioning protocol proofed to be a predictive parameter for lymphocyte subset reconstitution after HSCT. In the same way, the age of the recipient or donor did not essentially influence reconstitution of T cells. The source of graft and may be defined individual factors of the donor seem to be the most influencing factors that can be determined before transplantation. T cell reconstitution was negatively influenced by the use of ATG in unrelated donor HSCT and the lower T cell counts in BM grafts. These observations may reflect the pronounced impact of post-thymic T cell expansion during the first months after transplantation. Therefore, patients after HSCT from an unrelated or mismatched donor who receive ATG as well as patients after BMT represent a group with increased risk for delayed T cell reconstitution and infectious complications. Our data indicate that lymphocyte reconstitution in elderly patients is not different from young adult patients. Furthermore, the influence of risk factors for a delayed lymphocyte reconstitution was restricted to the first months, whereas there were comparable lymphocyte subset counts among all groups 1 year after alloHSCT.
